Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s650851 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Fan Bu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Ischemic Stroke, Drug Delivery Systems, Brain Ischemia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Reperfusion therapy has transformed acute ischemic stroke care, yet large-vessel recanalization does not ensure capillary reperfusion, preservation of the blood-brain barrier and neurovascular unit (BBB/NVU), or durable neurological recovery. Nanomedicine is still commonly judged by BBB crossing or ischemic-hemisphere accumulation, although vascular access, tissue viability, transport phenotype, thromboinflammation, and standard treatment change rapidly during the lifetime of a formulation. This narrative review proposes a conceptual framework that matches the reperfusion state and pathological interface to the compartment in which the therapeutically active entity must act. The framework is intended to organize preclinical evidence and generate testable translational hypotheses; it has not yet been clinically validated. Persistent occlusion may favor intravascular targets, whereas recanalization with no-reflow creates a distinct microvascular delivery problem. Early reperfusion injury may prioritize BBB/NVU stabilization, while later biological contexts may require selective immune, regenerative, or organelle-directed interventions. These contexts may coexist spatially, vary across vascular territories, and shift during treatment; they should therefore not be interpreted as a mandatory chronological sequence. We distinguish BBB crossing, controlled barrier modulation, and BBB/NVU repair as separate therapeutic tasks, and introduce transport attrition as a practical explanation for why sequential targeting, transcytosis, cellular uptake, endosomal escape, and organelle localization can yield little final active-entity exposure despite strong tissue imaging. Recent predominantly preclinical examples illustrate how thrombus-targeted rtPA systems, neutrophil-intercepting particles, NET-degrading polymersomes, lesion-targeted nanoplatforms, and mitochondrial nanomedicines may fit different delivery topologies. Translational credibility requires topology-resolved exposure, target engagement in viable tissue, hemocompatibility under antithrombotic treatment, state-appropriate models, function-linked manufacturing controls, and compatibility with thrombolysis and thrombectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, People's Republic of China.
- Department of Thoracic Surgery, Shenzhen People's Hospital, Shenzhen, Guangdong, People's Republic of China.
ORCID-Profile: Fan Bu, Fengjiao Chen, Yi Wen
Zitieren
APA
Bu, F., Cao, Y., Chen, F., Wen, Y., & Xiong, L. (2026). Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s650851
Vancouver
Bu F, Cao Y, Chen F, Wen Y, Xiong L. Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s650851
BibTeX
@article{Bu2026,
author = {Bu, Fan and Cao, YuanYuan and Chen, Fengjiao and Wen, Yi and Xiong, Lile},
title = {Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s650851}
}
EUVIMED